233 related articles for article (PubMed ID: 36419356)
1. Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD-1 inhibitor therapy.
Fang Q; Yu J; Li W; Luo J; Deng Q; Chen B; He Y; Zhang J; Zhou C
Clin Exp Pharmacol Physiol; 2023 Feb; 50(2):178-190. PubMed ID: 36419356
[TBL] [Abstract][Full Text] [Related]
2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
3. Association of Dynamic Changes in Peripheral Blood Indexes With Response to PD-1 Inhibitor-Based Combination Therapy and Survival Among Patients With Advanced Non-Small Cell Lung Cancer.
Chen Y; Wen S; Xia J; Du X; Wu Y; Pan B; Zhu W; Shen B
Front Immunol; 2021; 12():672271. PubMed ID: 34054853
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
Yamaguchi O; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Hashimoto K; Kobayashi K; Kagamu H
Oncology; 2024; 102(3):271-282. PubMed ID: 37725914
[TBL] [Abstract][Full Text] [Related]
7. Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study.
Zheng F; Meng Q; Zhang L; Chen J; Zhao L; Zhou Z; Liu Y
World J Surg Oncol; 2023 Jul; 21(1):198. PubMed ID: 37420219
[TBL] [Abstract][Full Text] [Related]
8. Assessment of systematic inflammatory and nutritional indexes in extensive-stage small-cell lung cancer treated with first-line chemotherapy and atezolizumab.
Qi WX; Xiang Y; Zhao S; Chen J
Cancer Immunol Immunother; 2021 Nov; 70(11):3199-3206. PubMed ID: 33796915
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Potential of the Prognostic Nutritional Index in Non-Small Cell Lung Cancer Patients Receiving Pembrolizumab Combination Therapy with Carboplatin and Paclitaxel/Nab-Paclitaxel.
Nishihara-Kato F; Imai H; Tsuda T; Wasamoto S; Nagai Y; Kishikawa T; Miura Y; Ono A; Yamada Y; Masubuchi K; Osaki T; Nakagawa J; Umeda Y; Minemura H; Kozu Y; Taniguchi H; Ohta H; Kaira K; Kagamu H
Oncology; 2024; 102(1):30-42. PubMed ID: 37598676
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
12. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
[TBL] [Abstract][Full Text] [Related]
13. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
[TBL] [Abstract][Full Text] [Related]
14. Combined systemic immune-inflammatory index and prognostic nutritional index predict outcomes in advanced non-small cell lung cancer patients receiving platinum-doublet chemotherapy.
Fan R; Chen Y; Xu G; Pan W; Lv Y; Zhang Z
Front Oncol; 2023; 13():996312. PubMed ID: 37077828
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of immune inflammation biomarkers in predicting survival and radiosensitivity in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Delikgoz Soykut E; Kemal Y; Karacin C; Karaoglanoglu O; Kurt M; Aytac Arslan S
J Med Imaging Radiat Oncol; 2022 Feb; 66(1):146-157. PubMed ID: 34632714
[TBL] [Abstract][Full Text] [Related]
16. Decreased monocyte-to-lymphocyte ratio was associated with satisfied outcomes of first-line PD-1 inhibitors plus chemotherapy in stage IIIB-IV non-small cell lung cancer.
Zheng L; Xiong A; Wang S; Xu J; Shen Y; Zhong R; Lu J; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
Front Immunol; 2023; 14():1094378. PubMed ID: 36776882
[TBL] [Abstract][Full Text] [Related]
17. Combining dynamics of serum inflammatory and nutritional indicators as novel biomarkers in immune checkpoint inhibitor treatment of non-small-cell lung cancer with bone metastases.
Asano Y; Hayashi K; Takeuchi A; Kato S; Miwa S; Taniguchi Y; Okuda M; Matsumoto I; Yano S; Demura S
Int Immunopharmacol; 2024 Jul; 136():112276. PubMed ID: 38820958
[TBL] [Abstract][Full Text] [Related]
18. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
Zhang Y; Kong FF; Zhu ZQ; Shan HX
BMC Cancer; 2023 Mar; 23(1):225. PubMed ID: 36894927
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
[TBL] [Abstract][Full Text] [Related]
20. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
